{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T23:47:51Z","timestamp":1769471271330,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian cancer (OC) is a highly lethal gynecological cancer. Olaparib maintenance therapy was effective and well-tolerated in pivotal RCTs. However, nationwide real-world safety information is limited in China. This multicenter, prospective, observational drug intensive monitoring study monitored the safety of olaparib in a largest-to-date, real-world Chinese OC cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible OC patients had received\u2009\u2265\u20091 dose of olaparib. Follow-up extended up to 30 days post-olaparib discontinuation or maximally for six months post-enrolment. Primary and secondary endpoints were adverse events (AEs) in all OC patients and in special populations (hepatically\/renally impaired before olaparib treatment; aged\u2009&gt;\u200965 years), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>By Jun 30, 2023, 799 patients from 33 sites were enrolled. By data cut-off (Dec 29, 2023), 796 patients treated with olaparib were analyzed. The median age was 55 years (range, 25\u201385). Of 796 patients, 490 (61.6%) were newly diagnosed and 306 (38.4%) had platinum-sensitive relapsed OC. AEs occurred in 343 (43.1%) patients, and 257 (32.3%) had treatment-related AEs. Anemia (19.2%) was the most common AE. Sixty-eight (8.5%) patients experienced grade\u2009\u2265\u20093 AEs, and 3 had AEs of special interest (AESIs; 0.4%; 1 myelodysplastic syndrome, 1 breast cancer, 1 pneumonitis). 45.2% (19\/42) patients with hepatic impairment at baseline, 38.5% (5\/13) with renal impairment at baseline and 38.6% (49\/127) aged\u2009&gt;\u200965 years experienced any AEs, respectively. No AESIs were reported in these subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this largest-to-date, first prospectively enrolled, real-world Chinese OC cohort, olaparib demonstrated a well-tolerated and manageable safety profile (including in special populations) with appropriate management, regardless of treatment lines. No new safety signals were identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-025-01924-8","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:23:27Z","timestamp":1765952607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC)"],"prefix":"10.1186","volume":"19","author":[{"given":"Li","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qionghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xipeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengxia","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liguo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhua","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congzhu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9221-6727","authenticated-orcid":false,"given":"Rutie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9891-2854","authenticated-orcid":false,"given":"Zhongqiu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"1924_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","DOI":"10.3322\/caac.21834"},{"issue":"3","key":"1924_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031845","volume":"25","author":"V Tavares","year":"2024","unstructured":"Tavares V, Marques IS, Melo IG, Assis J, Pereira D, Medeiros R. Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements. Int J Mol Sci. 2024;25(3):1845.","journal-title":"Int J Mol Sci"},{"key":"1924_CR3","unstructured":"Ferlay J, Ervik M, Lam F et al. Global Cancer Observatory: Cancer Today - China factsheet. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/160-china-fact-sheet.pdf. 2024. Accessed Aug 23, 2024."},{"issue":"7","key":"1924_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783\u201391.","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"1924_CR5","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1924_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2017.03.022","volume":"146","author":"R Salani","year":"2017","unstructured":"Salani R, Khanna N, Frimer M, Bristow RE, Chen LM. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: society of gynecologic oncology (SGO) recommendations. Gynecol Oncol. 2017;146(1):3\u201310.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1924_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/AOG.0000000000004173","volume":"137","author":"KC Kurnit","year":"2021","unstructured":"Kurnit KC, Fleming GF, Lengyel E. Updates and new options in advanced epithelial ovarian cancer treatment. Obstet Gynecol. 2021;137(1):108\u201321.","journal-title":"Obstet Gynecol"},{"issue":"10","key":"1924_CR8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(10):833\u201348.","journal-title":"Ann Oncol"},{"key":"1924_CR9","unstructured":"National Comprehensive Cancer Network. Ovarian Cancer, Version 1.2024. NCCN Clinical Practice Guidelines in Oncology. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf. 2024. Accessed Aug 23, 2024."},{"issue":"33","key":"1924_CR10","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1200\/JCO.22.01934","volume":"40","author":"WP Tew","year":"2022","unstructured":"Tew WP, Lacchetti C, Kohn EC. Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022;40(33):3878\u201381.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1924_CR11","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382\u201392.","journal-title":"N Engl J Med"},{"issue":"9","key":"1924_CR12","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384.","journal-title":"Lancet Oncol"},{"issue":"26","key":"1924_CR13","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"25","key":"1924_CR14","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"issue":"11","key":"1924_CR15","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763\u201374.","journal-title":"Adv Ther"},{"key":"1924_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1300199","volume":"13","author":"J Chen","year":"2024","unstructured":"Chen J, Zhang M, Li K, et al. A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China. Front Oncol. 2024;13:1300199.","journal-title":"Front Oncol"},{"key":"1924_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1336616","volume":"14","author":"J Chen","year":"2024","unstructured":"Chen J, Zhang M, Li K, et al. PARP inhibitor maintenance treatment for newly diagnosed ovarian cancer patients: a real-world study from China. Front Oncol. 2024;14:1336616.","journal-title":"Front Oncol"},{"issue":"1","key":"1924_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13048-019-0594-1","volume":"12","author":"J Ni","year":"2019","unstructured":"Ni J, Cheng X, Zhou R, Xu X, Guo W, Chen X. Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China. J Ovarian Res. 2019;12(1):117.","journal-title":"J Ovarian Res"},{"key":"1924_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.955124","volume":"12","author":"D Zhang","year":"2022","unstructured":"Zhang D, Li S, Zhang X, Peng J, Zhang S. What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: a real-world single-center retrospective cohort study from China. Front Oncol. 2022;12:955124.","journal-title":"Front Oncol"},{"issue":"9","key":"1924_CR20","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1158\/1535-7163.MCT-20-1064","volume":"20","author":"H Zheng","year":"2021","unstructured":"Zheng H, Gao Y, Guo H, et al. Real-world experience of olaparib treatment in patients with ovarian cancer: a Chinese multicenter study. Mol Cancer Ther. 2021;20(9):1735\u201342.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1924_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.prnil.2022.04.005","volume":"10","author":"J Pan","year":"2022","unstructured":"Pan J, Ye D, Zhu Y. Olaparib outcomes in metastatic castration-resistant prostate cancer: first real-world experience in safety and efficacy from the Chinese Mainland. Prostate Int. 2022;10(3):142\u20137.","journal-title":"Prostate Int"},{"issue":"11","key":"1924_CR22","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-21-3023","volume":"28","author":"Q Gao","year":"2022","unstructured":"Gao Q, Zhu J, Zhao W, et al. Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer: phase III trial (L-MOCA). Clin Cancer Res. 2022;28(11):2278\u201385.","journal-title":"Clin Cancer Res"},{"key":"1924_CR23","doi-asserted-by":"publisher","first-page":"851246","DOI":"10.3389\/fphar.2022.851246","volume":"13","author":"X Tian","year":"2022","unstructured":"Tian X, Chen L, Gai D, He S, Jiang X, Zhang N. Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS. Front Pharmacol. 2022;13:851246.","journal-title":"Front Pharmacol"},{"key":"1924_CR24","doi-asserted-by":"publisher","first-page":"1162665","DOI":"10.3389\/fphar.2023.1162665","volume":"14","author":"BA Maiorano","year":"2023","unstructured":"Maiorano BA, Maiorano MFP, Maiello E. Olaparib and advanced ovarian cancer: summary of the past and looking into the future. Front Pharmacol. 2023;14:1162665.","journal-title":"Front Pharmacol"},{"key":"1924_CR25","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.2147\/DDDT.S387920","volume":"16","author":"D Zhao","year":"2022","unstructured":"Zhao D, Long X, Wang J. Dose adjustment of poly (ADP\u2013ribose) polymerase inhibitors in patients with hepatic or renal impairment. Drug Des Devel Ther. 2022;16:3947\u201355.","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"1924_CR26","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40262-019-00754-4","volume":"58","author":"C Rolfo","year":"2019","unstructured":"Rolfo C, de Vos-Geelen J, Isambert N, et al. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and renal impairment. Clin Pharmacokinet. 2019;58(9):1165\u201374.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1924_CR27","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1111\/bcp.14283","volume":"86","author":"C Rolfo","year":"2020","unstructured":"Rolfo C, Isambert N, Italiano A, et al. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment. Br J Clin Pharmacol. 2020;86(9):1807\u201318.","journal-title":"Br J Clin Pharmacol"},{"key":"1924_CR28","doi-asserted-by":"publisher","first-page":"912256","DOI":"10.3389\/fphar.2022.912256","volume":"13","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, Ma P, Fu P, et al. Myelodysplastic syndrome\/acute myeloid leukemia following the use of poly-ADP ribose polymerase (PARP) inhibitors: a real-world analysis of postmarketing surveillance data. Front Pharmacol. 2022;13:912256.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1924_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/cpt.1103","volume":"105","author":"V Pilla Reddy","year":"2019","unstructured":"Pilla Reddy V, Bui K, Scarfe G, Zhou D, Learoyd M. Physiologically based pharmacokinetic modeling for olaparib dosing recommendations: bridging formulations, drug interactions, and patient populations. Clin Pharmacol Ther. 2019;105(1):229\u201341.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01924-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01924-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01924-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T13:44:12Z","timestamp":1769435052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-025-01924-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1924"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01924-8","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and any amendments thereof were reviewed and approved by the Ethics Committees of participating sites (2020-KY-039). All patients provided written informed consent prior to enrolment and patient information was kept under relevant data protection and privacy legislation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}